Brett Monia, a founding member of Ionis Pharmaceuticals, has been named the company’s COO.
Monia is currently the company’s senior vice president of drug discovery. In his new role he replaces Lynne Parshall, who has been with Ionis for 27 years and on Jan. 15 will become a strategic adviser to the company, which is a major player of the San Diego life sciences scene with a $7 billion market cap.
Monia has played a key role in leading the development of inotersen, designed to treat hereditary ATTR amyloidosis with polyneuropathy, in which abnormal protein buildup causes systemic problems that can be life threatening.
Ionis this month filed for approval of inotersen in the U.S. and Europe.
CEO Stanley Crooke announced Monia’s new position during the company’s recent third quarter earnings call. He said the move is a testament to the company’s succession planning.